Nanoparticles-based anti-aging treatment of Alzheimer's disease
Jian-Jian Chu1,2, Wen-Bo Ji1,2, Jian-Hua Zhuang1
1Second Affiliated Hospital (Changzheng Hospital) of Naval Medical University, Shanghai, China.
Abstract:
Age is the strongest risk factor for Alzheimer's disease (AD). In recent years, the relationship between aging and AD has been widely studied, with anti-aging therapeutics as the treatment for AD being one of the mainstream research directions. Therapeutics targeting senescent cells have shown improvement in AD symptoms and cerebral pathological changes, suggesting that anti-aging strategies may be a promising alternative for AD treatment. Nanoparticles represent an excellent approach for efficiently crossing the blood-brain barrier (BBB) to achieve better curative function and fewer side effects. Thereby, nanoparticles-based anti-aging treatment may exert potent anti-AD therapeutic efficacy. This review discusses the relationship between aging and AD and the application and prospect of anti-aging strategies and nanoparticle-based therapeutics in treating AD.
Insights
Aging accelerates Alzheimer's disease (AD). Targeting aging cells with nanoparticles offers a promising therapeutic strategy to combat AD by crossing the blood-brain barrier for improved treatment efficacy and reduced side effects.
Area of Science:
- Gerontology
- Neuroscience
- Biomedical Engineering
Background:
- Age is the primary risk factor for Alzheimer's disease (AD).
- Emerging research explores anti-aging therapeutics as a mainstream approach for AD treatment.
- Senolytics targeting senescent cells show potential in improving AD symptoms and pathology.
Purpose of the Study:
- To review the intricate relationship between aging and Alzheimer's disease.
- To discuss the therapeutic potential of anti-aging strategies for AD.
- To explore the application and future prospects of nanoparticle-based anti-aging treatments for AD.
Main Methods:
- Literature review on aging and AD.
- Analysis of senolytic therapies in AD models.
- Evaluation of nanoparticle drug delivery systems for brain targeting.
Main Results:
- Anti-aging strategies, particularly those targeting senescent cells, demonstrate efficacy in mitigating AD pathology and symptoms.
- Nanoparticles show promise for efficient blood-brain barrier (BBB) penetration, enhancing therapeutic delivery and minimizing side effects.
- Combined nanoparticle-based anti-aging approaches may offer potent therapeutic benefits for AD.
Conclusions:
- Anti-aging interventions represent a viable therapeutic avenue for Alzheimer's disease.
- Nanoparticle technology can facilitate targeted drug delivery across the BBB for enhanced anti-aging AD therapies.
- Further research into nanoparticle-mediated anti-aging treatments holds significant promise for future AD management.
More Related Videos
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...